{"id":"met233-and-met097","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bemiparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nadroparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Avoid","effect":"Increased risk of bleeding"}],"commonSideEffects":[],"contraindications":["Glucose-lowering medications","Pregnancy","Hypertension","Type 1 diabetes","Pancreatitis","Pancreatic cancer","Uncontrolled heart rate","Severe kidney issues","Significant weight-related health problems"]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=met233-and-met097","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:58.864258+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:12.021799+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:37:58.884957+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=met233-and-met097","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:12.759768+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1628401/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:13.970354+00:00"}},"allNames":"met233 and met097","offLabel":[],"timeline":[],"aiSummary":"MET233 and MET097, developed by Pfizer Inc., are marketed drugs with a revenue of $21.2B. They are used to treat Indication 1 and Indication 2. The drugs have undergone 1 trial and have 0 publications. Their mechanism of action is not specified on Wikipedia.","brandName":"MET233 and MET097","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for MET233 and MET097 involves interaction with the molecular target, but the specific details are not provided on Wikipedia. This lack of information makes it challenging for healthcare professionals to fully understand the drugs' effects and potential interactions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","patientPopulation":"~132","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=met233-and-met097","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=met233-and-met097","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:28:32.405753+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"MET233","company":"Metsera (Pfizer subsidiary)","advantage":"Combination with MET097"},{"name":"MET097","company":"Metsera (Pfizer subsidiary)","advantage":"Combination with MET233"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"met233-and-met097","indications":{"approved":[{"name":"Indication 1","regulator":"FDA"},{"name":"Indication 2","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06924320","phase":"PHASE1, PHASE2","title":"A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes","status":"RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2025-03-03","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":132}],"_emaApprovals":[{"date":"","name":"MET233 and MET097","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.biospace.com/press-releases/metsera-reports-second-quarter-2025-financial-results-and-continued-portfolio-progress","date":"2026-04-07","type":"news","title":"Metsera Reports Second Quarter 2025 Financial Results ... - BioSpace","source":"www.biospace.com"},{"url":"https://www.nasdaq.com/press-release/metsera-reports-positive-phase-2b-results-first-and-best-class-ultra-long-acting-glp","date":"2026-04-07","type":"news","title":"Metsera Reports Positive Phase 2b Results for First - Nasdaq","source":"www.nasdaq.com"},{"url":"https://www.edisongroup.com/research/pfizer-metsera-deal-offers-upside-potential/BM-2278/","date":"2026-04-07","type":"news","title":"IP Group — Pfizer-Metsera deal offers upside potential","source":"www.edisongroup.com"},{"url":"https://cdn.pfizer.com/pfizercom/product-pipeline/Q4%202025%20Pipeline%20Update_vFinal3.pdf?VersionId=XSLcQ04JnYn3Py.PPsUP_5lAboV.fDPh","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Pipeline","source":"cdn.pfizer.com"},{"url":"https://synapse.patsnap.com/drug/74c5e85d42704bada78c61c17191e04e","date":"2026-04-07","type":"news","title":"MET-233 - Drug Targets, Indications, Patents - Patsnap Synapse","source":"synapse.patsnap.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1628401"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"commercialAnalysis":{"text":"As a pharma industry analyst, I assess the commercial potential of MET233 and MET097, two promising candidates from Pfizer's portfolio. Currently, the revenue trajectory for these products is not explicitly stated in the provided sources. However, Metsera, the company developing these candidates, reported $530.9 million in cash and cash equivalents, which supports its runway into 2027 [1]. This indicates a solid financial foundation for the company to continue its development efforts.\n\nThe competitive landscape for MET233 and MET097 is evolving, with several players vying for market share in the obesity and metabolic disease space. Metsera's candidates have demonstrated promising results, with MET097i showing a mean placebo-subtracted weight loss of up to 14.1% after 28 weekly doses in the VESPER-1 trial [2]. This performance positions MET097i as a potential first- and best-in-class ultra-long acting GLP-1 receptor agonist. However, the company faces threats from established players, such as Novo Nordisk and Eli Lilly, which have a strong presence in the market.\n\nKey upcoming catalysts for MET233 and MET097 include the release of 12-week monotherapy data for MET233i in late 2025 [1] and the initiation of Phase 3 trials for MET097i in late 2025 [2]. Additionally, the company plans to release 12-week co-administration data for MET233i + MET097i by year-end 2025 or early 2026 [1]. These milestones will provide critical insights into the efficacy and safety of these candidates, potentially driving market interest and adoption.\n\nThe market outlook for MET233 and MET097 is promising, with Metsera's candidates poised to capitalize on the growing demand for effective treatments for obesity and metabolic diseases. As the company continues to advance its pipeline, we can expect to see increased competition and market activity in the coming years [3].","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.biospace.com/press-releases/metsera-reports-second-quarter-2025-financial-results-and-continued-portfolio-progress","date":"","title":"Metsera Reports Second Quarter 2025 Financial Results ... - BioSpace","source":"www.biospace.com"},{"url":"https://www.nasdaq.com/press-release/metsera-reports-positive-phase-2b-results-first-and-best-class-ultra-long-acting-glp","date":"","title":"Metsera Reports Positive Phase 2b Results for First - Nasdaq","source":"www.nasdaq.com"},{"url":"https://www.edisongroup.com/research/pfizer-metsera-deal-offers-upside-potential/BM-2278/","date":"","title":"IP Group — Pfizer-Metsera deal offers upside potential","source":"www.edisongroup.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:28:32.405753+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}